Matteo Vergati
Overview
Explore the profile of Matteo Vergati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
775
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krasniqi E, Filomeno L, Arcuri T, Di Lisa F, Astone A, Cutigni C, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682290
Background/objectives: HER2-positive breast cancer (HER2BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been...
2.
Di Lisa F, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, et al.
Front Oncol
. 2023 Jun;
13:1152123.
PMID: 37260975
Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine,...
3.
Vergati M, Krasniqi E, Monte G, Riondino S, Vallone D, Guadagni F, et al.
Curr Med Chem
. 2017 Jan;
24(12):1170-1185.
PMID: 28093985
Pre-clinical and clinical studies have investigated the role of a dysregulated metabolism in the sustainability of tumor initiation and progression. One of the most familiar metabolic alterations encountered in several...
4.
Ferroni P, Riondino S, Formica V, Cereda V, Tosetto L, La Farina F, et al.
Int J Cancer
. 2014 Jul;
136(5):1234-40.
PMID: 25042739
Neutrophil/lymphocyte (NLR) and platelet/lymphocyte (PLR) ratios might represent a yet unrecognized risk factor for venous thromboembolism (VTE) in cancer out-patients receiving chemotherapy. Accordingly, this study was aimed at analyzing the...
5.
Ferroni P, Guadagni F, Laudisi A, Vergati M, Riondino S, Russo A, et al.
Oncologist
. 2014 Apr;
19(5):562-7.
PMID: 24710308
Reduced estimated glomerular filtration rate (eGFR) has been associated with increased venous thromboembolism (VTE) risk in the general population. VTE incidence significantly increases in cancer patients, especially those undergoing chemotherapy....
6.
Jochems C, Tucker J, Vergati M, Boyerinas B, Gulley J, Schlom J, et al.
Cancer Immunol Immunother
. 2013 Nov;
63(2):161-74.
PMID: 24233342
The MUC1 tumor-associated antigen is overexpressed in the majority of human carcinomas and several hematologic malignancies. Much attention has been paid to the hypoglycosylated variable number of tandem repeats (VNTR)...
7.
Madan R, Tsang K, Bilusic M, Vergati M, Poole D, Jochems C, et al.
Oncologist
. 2013 Jul;
18(7):821-2.
PMID: 23847257
Background: Talactoferrin alfa (talactoferrin), an agent with immune-stimulating properties, has demonstrated safety and preliminary efficacy in clinical trials. Methods: Ten patients (five males and five females) with stage IV non-small...
8.
Vergati M, Della-Morte D, Ferroni P, Cereda V, Tosetto L, La Farina F, et al.
Rejuvenation Res
. 2013 Mar;
16(3):224-31.
PMID: 23521603
Data on the relationship between aging, chemotherapy, and risk for venous thromboembolism (VTE) are controversial. We sought to evaluate the risk of chemotherapy-associated VTE in young to middle-aged (YMA) and...
9.
Roselli M, Ferroni P, Riondino S, Mariotti S, Laudisi A, Vergati M, et al.
Int J Cancer
. 2013 Feb;
133(5):1253-8.
PMID: 23404208
Chemotherapy has been associated with an increased risk of venous thromboembolism (VTE). However, the prevalence of coagulation abnormalities or VTE occurrence as a consequence of different anti-cancer agents or treatment...
10.
Huen N, Pang A, Tucker J, Lee T, Vergati M, Jochems C, et al.
Int J Cancer
. 2013 Jan;
133(2):373-82.
PMID: 23319273
A higher frequency of regulatory T cells (Tregs) has been observed in peripheral blood mononuclear cells (PBMC) of patients with different types of solid tumors and hematological malignancies as compared...